Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 4 de 4
1.
J Transl Med ; 22(1): 462, 2024 May 15.
Article En | MEDLINE | ID: mdl-38750555

BACKGROUND: Comprehensive next-generation sequencing is widely used for precision oncology and precision prevention approaches. We aimed to determine the yield of actionable gene variants, the capacity to uncover hereditary predisposition and liquid biopsy appropriateness instead of, or in addition to, tumor tissue analysis, in a real-world cohort of cancer patients, who may benefit the most from comprehensive genomic profiling. METHODS: Seventy-eight matched germline/tumor tissue/liquid biopsy DNA and RNA samples were profiled using the Hereditary Cancer Panel (germline) and the TruSight Oncology 500 panel (tumor tissue/cfDNA) from 23 patients consecutively enrolled at our center according to at least one of the following criteria: no available therapeutic options; long responding patients potentially fit for other therapies; rare tumor; suspected hereditary cancer; primary cancer with high metastatic potential; tumor of unknown primary origin. Variants were annotated for OncoKB and AMP/ASCO/CAP classification. RESULTS: The overall yield of actionable somatic and germline variants was 57% (13/23 patients), and 43.5%, excluding variants previously identified by somatic or germline routine testing. The accuracy of tumor/cfDNA germline-focused analysis was demonstrated by overlapping results of germline testing. Five germline variants in BRCA1, VHL, CHEK1, ATM genes would have been missed without extended genomic profiling. A previously undetected BRAF p.V600E mutation was emblematic of the clinical utility of this approach in a patient with a liver undifferentiated embryonal sarcoma responsive to BRAF/MEK inhibition. CONCLUSIONS: Our study confirms the clinical relevance of performing extended parallel tumor DNA and cfDNA testing to broaden therapeutic options, to longitudinally monitor cfDNA during patient treatment, and to uncover possible hereditary predisposition following tumor sequencing in patient care.


Genomics , Germ-Line Mutation , Neoplasms , Humans , Female , Liquid Biopsy , Neoplasms/genetics , Neoplasms/pathology , Male , Middle Aged , Cohort Studies , Germ-Line Mutation/genetics , Genomics/methods , Adult , Aged , Germ Cells/metabolism , High-Throughput Nucleotide Sequencing/methods , Genetic Predisposition to Disease
3.
Pathologica ; 107(1): 22-3, 2015 Mar.
Article En | MEDLINE | ID: mdl-26591628

Segmental infarction (SI) of the testis is a rare condition that can masquerade as a mass lesion, thus requiring exclusion of tumour. If clinical exams do not exclude a neoplastic lesion with certainty, orchidectomy is usually performed. A case of SI of the testis is presented; the use of frozen section of the enucleated mass demonstrated the ischaemic nature of the lesion, so avoiding orchidectomy. The 8 year follow-up was uneventful. The use of frozen section in SI could permit the selection of cases in which testicular-sparing surgery should be considered.


Frozen Sections , Infarction/pathology , Orchiectomy , Testicular Neoplasms/pathology , Testis/blood supply , Testis/pathology , Unnecessary Procedures , Adult , Diagnosis, Differential , Humans , Infarction/surgery , Male , Predictive Value of Tests , Testicular Neoplasms/surgery , Testis/surgery
4.
Pathologica ; 95(3): 167-9, 2003 Jun.
Article It | MEDLINE | ID: mdl-12968313

A case of parosteal ossifyng lipoma of femour in 67 years-old female patient is described. Review of literature (1966-1999) about parosteal lipoma reveals less then 70 referred cases; much less common is the ossifyng type; in our knowledge five cases of this very rare subtype are referred in last thirty years.


Femur , Lipoma/pathology , Ossification, Heterotopic/pathology , Soft Tissue Neoplasms/pathology , Aged , Female , Humans
...